Drug Costs

Build Back Better Act: Health Coverage Provisions Explained

On November 19, 2021, the House of Representatives passed the Build Back Better Act, the budget reconciliation bill, with the Senate expected to consider the legislation in coming weeks. The Build Back Better Act includes numerous provisions that would dramatically strengthen and expand both public and private health insurance coverage. Some of the new provisions […]

Build Back Better Reconciliation Bill Would Take Big Strides in Expanding Health Coverage and Access for Children and Families

[Editor’s Note: The U.S. House of Representatives approved a revised Build Back Better Act budget reconciliation bill on November 19, 2021. This brief  by Georgetown University CCF and CHIR explain the Medicaid, CHIP, and private health insurance provisions.]  Yesterday, the House Rules Committee unveiled a compromise reconciliation bill which includes numerous provisions that dramatically strengthen […]

Commonwealth Fund Blog Series on Medicaid Drug Pricing Issues

Congress and the Biden Administration are currently pursuing substantial drug pricing reforms as part of the reconciliation legislation expected to move this fall.  While the focus is primarily on Medicare, Medicaid should not be overlooked. In an ongoing series of posts for the Commonwealth Fund’s To the Point blog, I examine some key Medicaid drug […]

New CBO Study Compares Net Prices for Brand-Name Drugs Among Federal Programs, Finds Medicaid Gets Largest Discounts

In a new groundbreaking study, the Congressional Budget Office compared brand-name drug prices, net of rebates and discounts, across select federal programs and agencies including Medicaid, Medicare Part D and the Department of Veterans Affairs (VA).  It found that Medicaid gets the lowest net prices, far below that of Medicare Part D plans and well […]